Flotetuzumab

Published

dm+d

Unassigned

New Medicines

Acute myeloid leukaemia (AML), primary induction failure or early relapse (PIF/ER)

Information

New molecular entity
Servier
MacroGenics

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase II Clinical Trials
Yes

Category

A humanised CD123 and CD3 bispecific antibody
AML is the most common acute leukaemia in adults. The incidence of the AMLs in European adults is 5-8 cases per 100,000 [1].
Acute myeloid leukaemia (AML), primary induction failure or early relapse (PIF/ER)
Intravenous infusion